This is a most useless board full of one liners sitting in front of a monitor watching the price of CUR and posting out of sheer excitement.
Take today's move, rather than looking for news or considering technical analysis or some intelligent question/answer, all we get is pumping and cheering.
Before you longs start name calling, I am long and bullish on CUR. Now you longs go ahead and insult me.
Also CUR was mentioned in a "blog" about SRPT as to whether or not "retail" can scoop analysts on share price appreciation and results in biotechs due to new technology of social media, etc. IMO
Lately I`ve been watching shares of Neuralstem (CUR). The company recently completed a phase I trial testing NSI-566, a mixture of human neural stem cells injected directly into a patients lumbar or cervical spinal cord for the treatment of Amyotrophic Lateral Sclerosis (ALS). The phase I trial was a 15 patient open-label design. Neuralstem published preliminary results from the first 12 patients of the trial in Stem Cells (2012;30:1144-1151). Since that time, three new patients and three returning patients have received new injections of NSI-566.
Analysis of the ongoing phase 1 trial in ALS continues. The final patient was treated with five unilateral cervical injections in August 2012. The last three patients treated (patients #16, #17, and #18) all previously completed ten bilateral lumbar spinal cord injections (patients #10, #11, and #12). The data published in Stem Cell showed clear signs of disease stabilization in a subset of ambulatory patients on the ALS Functional Rating Scale (ALSFRS-R), as well as a Forced Vital Capacity (FVC) and Hand-Held Dynamometer (HHD) scales. If we know anything about ALS, it`s that it is a rapidly progressive and degenerative disease. Patients do not spontaneously stabilize.
One patient (#11), named Ted Harada, showed significant improvement in motor function. Mr. Harada`s improvements were so much so that he was able to walk without a cane. Physicians even had to re-diagnose his disease to confirm ALS after his unprecedented improvement following lumbar spinal cord injections of NSI-566.
Similar to what we saw above with Sarepta and eteplirsen, Mr. Harada discussed his results with local media (source). An article by Crain`s Detroit Business (link) highlighted the success of Mr. Harada, and another ALS patient, Ed Tessaro, after receiving another round of treatment. There`s even a video interview of both Mr. Harada and Mr. Tessaro discussing their experiences with NSI-566. Continue reading by clicking here.
.Fair enough! Here is my take in today's price spike.
1-My search of about 15min did not find any "relevant" news.
2-Volume and trade voracity plus individual trade-size and block trades (shown in my setup and easy to monitor) seemed bullish and sustainable.
3-Further, and encouraging, CUR had dropped to a low of 0.88 prior to the rise which I saw and see as bullish. It is my experience that prior to substantial gains price dips (or is it made so?) and such was the case today.